Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study

BACKGROUND: Sorafenib is a multiple receptor tyrosine kinase inhibitor known to prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). Predicting this drug’s survival benefits is challenging because clinical responses are rarely measurable during treatment. In this study,...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:BMC Cancer
Prif Awduron: Hayashi, Tomoyuki, Yamashita, Taro, Terashima, Takeshi, Suda, Tsuyoshi, Okada, Hikari, Asahina, Yoshiro, Hayashi, Takehiro, Hara, Yasumasa, Nio, Kouki, Sunagozaka, Hajime, Takatori, Hajime, Arai, Kuniaki, Sakai, Yoshio, Yamashita, Tatsuya, Mizukoshi, Eishiro, Honda, Masao, Kaneko, Shuichi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2017
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5738185/
https://ncbi.nlm.nih.gov/pubmed/29258450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3889-x
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg